|
JANUARY 8, 2025
STOMP Trial Stomped by DSMB—Tecovirimat Did Not Improve Mpox Resolution or Pain
By IDSE New Staff
The antiviral drug tecovirimat (Tpoxx, SIGA Technologies) did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international STOMP trial.
Therefore, the study’s data safety and monitoring board (DSMB) recommended stopping further enrollment of participants who were being randomized to tecovirimat or placebo. The National Institute of Allergy and Infectious Diseases accepted the DSMB’s recommendation. Given the lack of an efficacy signal, NIAID also closed enrollment into an open-label study arm for participants with or at elevated risk for severe disease that was not designed to estimate the drug’s efficacy.
The National Institute of Allergy and Infectious Diseases accepted the DSMB’s recommendation. Given the lack of an efficacy signal, NIAID also closed enrollment into an open-label study arm for participants with or at elevated risk for severe disease that was not designed to estimate the drug’s efficacy.
Continue reading... https://www.idse.net/Zoonotic-Diseases/Article/01-25/STOMP-Trial-Stomped-by-DSMB-Tecovirimat-Did-Not-Improve-Mpox-Resolution-or-Pain/75897
"Reproduced with permission - Infectious Disease Special Edition (IDSE)"
Infectious Disease Special Edition (IDSE)
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News
|
